Kent Hawryluk, MBX Biosciences CEO (via IUPUI School of Science)

RA Cap­i­tal jumps aboard nine-fig­ure round for the en­docrine biotech co-found­ed by Hu­ma­log in­ven­tor

In the sum­mer of 2020, a suc­cess­ful sci­en­tist/in­vestor team took the wraps off their lat­est project in MBX Bio­sciences. But at the time, they left most gran­u­lar de­tails up to the imag­i­na­tion.

On Mon­day, MBX re­vealed what it’s been work­ing on and how it plans to move for­ward.

The biotech, helmed by CEO Kent Hawry­luk and his long­time busi­ness part­ner and CSO Richard Di­Marchi, closed a $115 mil­lion Se­ries B round Mon­day, led by Welling­ton Man­age­ment. RA Cap­i­tal — the Pe­ter Kolchin­sky/Ra­jeev Shah-led firm with a knack for steer­ing quick Nas­daq leaps — al­so chipped in.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.